XOMA — XOMA Royalty Corp. stock price, charts and financials

Latest market price

40.17

+0.00%

Overview Short InterestFilings

XOMAQT66XOMA Royalty Corp.·NASDAQ

Overview Short InterestFilings

40.17+0.00%

Loading chart...

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	25.59	EPS (ttm)	1.57	Insider Own	39.79%	Shs Outstand	12.54M	Perf Week	0.00%

Market Cap	503.77M	Forward P/E	-	EPS next Y	-0.05	Insider Trans	0.00%	Shs Float	11.97M	Perf Month	-4.11%

Enterprise Value	533.77M	PEG	2.08	EPS next Q	-	Inst Own	-	Short Float	7.65%	Perf Quarter	0.43%

Income	31.00M	P/S	14.39	EPS this Y	-49.99%	Inst Trans	-	Short Ratio	4.10	Perf Half Y	52.33%

Sales	35.00M	P/B	4.46	EPS next Y	-106.10%	ROA	11.59%	Short Interest	914.94K	Perf YTD	51.07%

Book/sh	9.01	P/C	5.30	EPS next 5Y	12.33%	ROE	30.21%	52W High	45.22 -11.17%	Perf Year	56.49%

Cash/sh	7.58	P/FCF	75.94	EPS past 3/5Y	- 13.36%	ROIC	1.94%	52W Low	22.29 80.22%	Perf 3Y	142.72%

Dividend Est.	-	EV/EBITDA	10.68	Sales past 3/5Y	105.41% 12.39%	Gross Margin	93.29%	Volatility	0.00% 1.50%	Perf 5Y	22.32%

Dividend TTM	-	EV/Sales	15.25	EPS Y/Y TTM	195.15%	Oper. Margin	13.73%	ATR (14)	0.59	Perf 10Y	278.96%

Dividend Ex-Date	-	Quick Ratio	3.59	Sales Y/Y TTM	25.00%	Profit Margin	86.97%	RSI (14)	34.34	Recom	2.50

Dividend Gr. 3/5Y	-	Current Ratio	3.59	EPS Q/Q	183.33%	SMA20	-4.55%	Beta	0.86	Target Price	44.50

Payout	17.54%	Debt/Eq	1.25	Sales Q/Q	-25.00%	SMA50	-4.17%	Rel Volume	0.00	Prev Close	40.17

Employees	14	LT Debt/Eq	1.13	Earnings	Aug 12	SMA200	18.90%	Avg Volume	318.73K	Price	40.17

IPO Date	Jun 06, 1986	Option/Short	Yes / Yes	EPS/Sales Surpr.	32.33% 0.26%	Net Debt/EBITDA	0.60	Volume	0	Change	0.00%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Apr-30-26	Downgrade	HC Wainwright & Co.	Buy → Neutral	$97 → $39
Feb-24-26	Reiterated	Leerink Partners	Outperform	$45 → $50
Dec-12-25	Reiterated	Stifel Nicolaus		$50
Dec-11-25	Reiterated	Leerink Partners	Outperform	$45
Dec-11-25	Reiterated	HC Wainwright & Co.	Buy	$97
Dec-09-25	Initiated	Lucid Capital	Buy	$76
Sep-07-21	Downgrade	Wedbush	Outperform → Neutral
Sep-05-17	Upgrade	Wedbush	Neutral → Outperform
Nov-14-16	Downgrade	Wedbush	Outperform → Neutral
Jul-23-15	Downgrade	Jefferies	Buy → Hold

Latest News

Jul-14-26

Jul-14-2609:00AM

XOMA Royalty Announces Closing of Its Acquisition by Ligandglobenewswire.com

09:00AM

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assetsglobenewswire.com

Company

XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	35	52	28	5	6	38	29	18	5
Cost of Goods Sold Incl. D&A	3	3	0	0	0	0	0	1	2
Gross Profit	32	49	28	5	6	38	29	17	4
Selling, General and Administrative Excl. Other	40	36	34	27	23	20	17	21	19
Research and Development	0	2	3	0	0	0	0	1	2
Other Operating Expense	-11	0	31	19	0	0	0	-1	-1
Operating Income	6	11	-40	-42	-17	18	12	-4	-17
Interest Expense	12	13	14	1	0	0	2	2	1
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	42	33	34	2	0	-1	1	4	4
Net Income Before Taxes	33	32	-19	-41	-17	16	12	-2	-13
Income Taxes	0	0	-6	0	0	0	-2	0	0
Consolidated Net Income	31	32	-14	-41	-17	16	13	-2	-13
Net Income From Continuing Operations	33	32	-14	-41	-17	16	13	-2	-13
Net Income	31	32	-14	-41	-17	16	13	-2	-13
EPS (Recurring)	1.65	1.53	-1.65	-4.04	-1.98	0.69	0.82	-0.88	-1.59
EPS (Basic, Before Extraordinaries)	1.65	1.53	-1.65	-4.04	-1.98	0.69	0.82	-0.88	-1.59
EPS (Diluted)	1.57	1.46	-1.65	-4.04	-1.98	0.65	0.78	-0.88	-1.59
EBITDA	50	48	-5	-23	-17	17	14	-4	-12
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	25.59	18.21	—	—	—	32.08	56.58	—	—
Price To Sales Ratio	13.77	9.20	11.26	40.70	33.73	6.04	16.74	13.65	20.24
Gross Margin	91.43	94.23	100.00	100.00	100.00	100.00	100.00	94.44	80.00
Operating Margin	17.14	21.15	-142.86	-840.00	-283.33	47.37	41.38	-22.22	-340.00
Net Margin	88.57	61.54	-50.00	-820.00	-283.33	42.11	44.83	-11.11	-260.00
Shares Outstanding	12	18	12	11	11	11	11	9	8
Market Capitalization	482	479	315	204	202	229	485	246	101
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Trigilio Jeffrey	Chief Financial Officer	Apr 20 '26	Option Exercise	0.00	11,538	0	103,906	Apr 22
Montano Maricel Perea	Chief Legal Officer	Apr 20 '26	Option Exercise	0.00	3,370	0	41,793	Apr 22
Hughes Owen	Chief Executive Officer	Apr 20 '26	Option Exercise	0.00	10,568	0	191,264	Apr 22
Sitko Bradley	Chief Investment Officer	Apr 20 '26	Option Exercise	0.00	3,737	0	82,961	Apr 22
Trigilio Jeffrey	Chief Financial Officer	Apr 13 '26	Option Exercise	0.00	4,000	0	94,000	Apr 15
LIMBER JOSEPH M	Director	Mar 27 '26	Option Exercise	11.20	3,026	33,891	9,234	Mar 31
WYSZOMIERSKI JACK L	Director	Mar 24 '26	Option Exercise	11.20	3,026	33,891	21,530	Mar 26
Hughes Owen	Chief Executive Officer	Dec 04 '25	Buy	25.05	100,000	2,505,000	102,000	Dec 08
BURNS THOMAS M.	SVP, Finance & CFO	Sep 22 '25	Sale	35.99	4,330	155,820	30,079	Sep 23
Sitko Bradley	Chief Investment Officer	Sep 19 '25	Option Exercise	0.00	6,712	0	19,822	Sep 23
Hughes Owen	Chief Executive Officer	Sep 19 '25	Option Exercise	0.00	35,567	0	98,268	Sep 23
BURNS THOMAS M.	SVP, Finance & CFO	Sep 19 '25	Option Exercise	0.00	11,846	0	34,409	Sep 23
Montano Maricel Perea	Chief Legal Officer	Sep 19 '25	Option Exercise	0.00	3,033	0	12,134	Sep 23
Montano Maricel Perea	Chief Legal Officer	Sep 10 '25	Option Exercise	0.00	9,101	0	9,101	Sep 12
Sitko Bradley	Chief Investment Officer	Jun 30 '25	Buy	25.39	2,000	50,780	7,045	Jul 02

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.